- Home
- KDK vs ANAB Comparison
KDK vs ANAB Comparison
Compare KDK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KDK | ANAB |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KDK | ANAB |
|---|---|---|
| Price | $3.56 | $55.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $15.38 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 956.3K | 356.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | $3,797,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $236.00 | N/A |
| Revenue Next Year | $459.11 | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $3.49 | $17.11 |
| 52 Week High | $11.35 | $73.30 |
Technical Indicators
Market Signals| Indicator | KDK | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 48.19 |
| Support Level | N/A | $53.46 |
| Resistance Level | $4.65 | $57.70 |
| Average True Range (ATR) | 0.19 | 2.20 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 17.85 | 31.50 |
Price Performance
Historical ComparisonAbout KDK Kodiak AI Inc.
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).